European Society of Human Reproduction and Embryology (ESHRE) 39th Annual Meeting

Relugolix combo reduces dysmenorrhea, NMPP in premenopausal women

Elaine Soliven, 20230817000000

The use of relugolix 40 mg in combination with oestradiol 1 mg and norethisterone acetate 0.5 mg (relugolix combination therapy [relugolix-CT]) significantly reduced dysmenorrhea and nonmenstrual pelvic pain (NMPP) in premenopausal women with endometriosis who received prior hormonal treatment, according to a post hoc analysis of two phase III trials presented at ESHRE 2023.

Linzagolix promising for endometriosis-associated pain

Elaine Soliven, 20230816000000

Once-daily treatment with linzagolix, a novel, oral GnRH* antagonist, with or without add-back therapy (ABT), reduces dysmenorrhoea and nonmenstrual pelvic pain (NMPP), among women with endometriosis, according to the EDELWEISS 3 trial presented at ESHRE 2023.

Testosterone pretreatment of no benefit to women at risk of poor response to IVF

Jairia Dela Cruz, 20230814140000

Treatment with transdermal testosterone prior to initiating ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) does not appear to increase the chances of becoming pregnant for women at risk of having a poor ovarian response, as shown in the T-TRANSPORT trial presented at ESHRE 2023.

Does PCOS increase cardiovascular risk in women?

Stephen Padilla, 20230814120000

A strong association exists between polycystic ovarian syndrome (PCOS) and cardiovascular risk factors, but women with PCOS 40‒60 years of age are not at greater risk of cardiovascular morbidity and mortality, suggest the results of a study presented at the recent ESHRE 2023.

Is ChatGPT reliable in answering questions about fertility?

Stephen Padilla, 20230814110000

Answers given by ChatGPT to questions about fertility yield high-quality information with little evidence of commercial bias, according to a study presented at ESHRE 2023.

Progesterone may raise chances of having a baby for couples with unexplained infertility

Jairia Dela Cruz, 20230813090000

Couples with unexplained infertility who are seeking parenthood may benefit from progesterone treatment, which can increase the livebirth rates and decrease miscarriage rates by twofold, according to data from the PiNC* trial.